Impact of lenvatinib on OATP1B activity in patients with hepatocellular carcinoma

Aims Lenvatinib (LEN) inhibits organic anion transporting polypeptide 1B1 (OATP1B1) in vitro, raising concern about drug–drug interactions (DDIs). We evaluated the in vivo impact of LEN on OATP1B activity in hepatocellular carcinoma (HCC), using coproporphyrin‐I (CP‐I) as endogenous biomarker. Methods Twenty‐six patients with HCC received LEN in this prospective, single‐centre, observational study. Plasma CP‐I and total and unbound LEN concentrations were measured at baseline and for 24 h after the first dose. DDI risk was assessed using the ICH M12 basic static model. Changes from baseline were analysed using a linear mixed‐effects model on log‐transformed concentrations with Dunnett's multiple comparisons and expressed as geometric mean ratios (GMR) with 95% confidence intervals (CIs). Results No significant changes in plasma CP‐I from baseline were observed at any time point, regardless of OATP1B1 genotype or hepatic function (adjusted p ≥ .25 in all comparisons). Whole‐cohort GMRs ranged from 0.97 to 1.11, with upper limit of 95% CI not exceeding 1.30. Baseline CP‐I did not differ by genotype ( p = .578) but was higher in Child–Pugh B than A ( p = .013). Using the basic static model, the median estimated C max ,inlet,u‐to‐IC 50 ,u ratio was 0.009, well below the 0.1 threshold. Conclusions LEN did not significantly alter OATP1B activity in HCC patients, concordant with static model prediction that first‐dose unbound LEN concentrations were far below the threshold for OATP1B1 inhibition. LEN‐attributable OATP1B1‐mediated DDI risk is therefore low, although this does not account for the reduced baseline OATP1B function inherent to HCC. Caution is warranted when extrapolating these findings to preserved hepatic function.

Authors

Institutions

Publication Details

Journal
British Journal of Clinical Pharmacology
Published
2026-11-16
DOI
https://doi.org/10.1002/bcp.70921
Primary Topic
Drug Transport and Resistance Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Impact of lenvatinib on OATP1B activity in patients with hepatocellular carcinoma

Ken Shiraiwa, Ryosuke Tatsuta, Daiki Toyama, Yosuke Suzuki et al.
2 links
British Journal of Clinical Pharmacology
Drug Transport and Resistance Mechanisms
article

Impact of lenvatinib on OATP1B activity in patients with hepatocellular carcinoma

Ken Shiraiwa, Ryosuke Tatsuta, Daiki Toyama, Yosuke Suzuki, Hironori Abe, Ryota Tanaka, Yoshio Sueshige, Hiroki Itoh, Keiko Ohno, Ayako Oda, Haruki Sato
article en

Abstract

Aims Lenvatinib (LEN) inhibits organic anion transporting polypeptide 1B1 (OATP1B1) in vitro, raising concern about drug–drug interactions (DDIs). We evaluated the in vivo impact of LEN on OATP1B activity in hepatocellular carcinoma (HCC), using coproporphyrin‐I (CP‐I) as endogenous biomarker. Methods Twenty‐six patients with HCC received LEN in this prospective, single‐centre, observational study. Plasma CP‐I and total and unbound LEN concentrations were measured at baseline and for 24 h after the first dose. DDI risk was assessed using the ICH M12 basic static model. Changes from baseline were analysed using a linear mixed‐effects model on log‐transformed concentrations with Dunnett's multiple comparisons and expressed as geometric mean ratios (GMR) with 95% confidence intervals (CIs). Results No significant changes in plasma CP‐I from baseline were observed at any time point, regardless of OATP1B1 genotype or hepatic function (adjusted p ≥ .25 in all comparisons). Whole‐cohort GMRs ranged from 0.97 to 1.11, with upper limit of 95% CI not exceeding 1.30. Baseline CP‐I did not differ by genotype ( p = .578) but was higher in Child–Pugh B than A ( p = .013). Using the basic static model, the median estimated C max ,inlet,u‐to‐IC 50 ,u ratio was 0.009, well below the 0.1 threshold. Conclusions LEN did not significantly alter OATP1B activity in HCC patients, concordant with static model prediction that first‐dose unbound LEN concentrations were far below the threshold for OATP1B1 inhibition. LEN‐attributable OATP1B1‐mediated DDI risk is therefore low, although this does not account for the reduced baseline OATP1B function inherent to HCC. Caution is warranted when extrapolating these findings to preserved hepatic function.

British Journal of Clinical Pharmacology
Meiji Pharmaceutical University (JP), Oita University Hospital (JP)
Good health and well-being
Drug Transport and Resistance Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon